169 related articles for article (PubMed ID: 9571744)
1. In vitro activity of cefpirome against microorganisms isolated in haematology, oncology and intensive care units in Switzerland.
Liassine N; Bille J; Breer C; Frei R; Wüst J; Auckenthaler R
Scand J Infect Dis; 1997; 29(6):615-21. PubMed ID: 9571744
[TBL] [Abstract][Full Text] [Related]
2. Cross-susceptibility of cefpirome and four other beta-lactams against isolates from haematology/oncology and intensive care units. International Study Group.
Spencer RC
Scand J Infect Dis Suppl; 1993; 91():25-32. PubMed ID: 8290900
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan. Japan Antimicrobial Resistance Study Group.
Yamaguchi K; Mathai D; Biedenbach DJ; Lewis MT; Gales AC; Jones RN
Diagn Microbiol Infect Dis; 1999 Jun; 34(2):123-34. PubMed ID: 10354863
[TBL] [Abstract][Full Text] [Related]
4. Comparative in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology units. Belgian Multicentre Study Group.
Piérard D; Emmerechts K; Lauwers S
J Antimicrob Chemother; 1998 Apr; 41(4):443-50. PubMed ID: 9598775
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of cefpirome compared with other third generation cephalosporins against nosocomial isolates in Argentina.
Casellas JM; Goldberg M; Orellana N; Morosini MI; Negri MC; Arduino S
Infection; 1990; 18(3):193-5. PubMed ID: 2114372
[TBL] [Abstract][Full Text] [Related]
6. [In vitro antimicrobial activity of cefpirome compared to other broad-spectrum beta-lactam drugs against 804 clinical isolates from 9 Brazilian hospitals].
Sader HS; Mendes CM; Montelli A; Sampaio J; Segura AJ; Kesselring GL; Costa L; Ribeiro JE; Mamizuka E; Mimiça I
Rev Assoc Med Bras (1992); 1998; 44(4):283-8. PubMed ID: 9852647
[TBL] [Abstract][Full Text] [Related]
7. The antimicrobial activity and beta-lactamase stability of cefpirome, a new fourth-generation cephalosporin in comparison with other agents.
Cheng AF; Ling TK; Lam AW; Fung KS; Wise R
J Antimicrob Chemother; 1993 May; 31(5):699-709. PubMed ID: 8335498
[TBL] [Abstract][Full Text] [Related]
8. The activity of cefpirome and ten other antibacterial agents against 2858 clinical isolates collected from 20 centres.
Reeves DS; Bywater MJ; Holt HA
J Antimicrob Chemother; 1993 Mar; 31(3):345-62. PubMed ID: 8486569
[TBL] [Abstract][Full Text] [Related]
9. Multicentre comparative study on the antibacterial activity of FK-037, a new parenteral cephalosporin.
Martínez-Beltrán J; Cantón R; Liñares J; García de Lomas J; Gimeno C; Tubau F; Baquero F
Eur J Clin Microbiol Infect Dis; 1995 Mar; 14(3):244-52. PubMed ID: 7614970
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin.
Nishino T; Otsuki M; Hatano K; Nishihara Y
Chemotherapy; 1994; 40(3):167-82. PubMed ID: 8205935
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity and stability against novel beta-lactamases of investigational beta-lactams (cefepime, cefpirome, flomoxef, SCE2787 and piperacillin plus tazobactam) in comparison with established compounds (cefotaxime, latamoxef and piperacillin).
Bauernfeind A; Schweighart S; Eberlein E; Jungwirth R
Infection; 1991; 19 Suppl 5():S264-75. PubMed ID: 1664418
[TBL] [Abstract][Full Text] [Related]
12. Comparative in-vitro activity of Sch 34343, imipenem, cefpirome and cefotaxime.
Bauernfeind A
J Antimicrob Chemother; 1985 Jun; 15 Suppl C():155-64. PubMed ID: 3897170
[TBL] [Abstract][Full Text] [Related]
13. In vitro antibacterial activities of FK037: a new parenteral cephalosporin.
Inoue K; Inoue E; Mitsuhashi S
Chemotherapy; 1995; 41(4):257-66. PubMed ID: 7555206
[TBL] [Abstract][Full Text] [Related]
14. In-vitro antimicrobial activity of Cefpirome: a new fourth-generation cephalosporin against clinically significant bacteria.
Hafeez S; Izhar M; Ahmed A; Zafar A; Naeem M
J Pak Med Assoc; 2000 Aug; 50(8):250-2. PubMed ID: 10992706
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin.
Pillar CM; Aranza MK; Shah D; Sahm DF
J Antimicrob Chemother; 2008 Mar; 61(3):595-602. PubMed ID: 18218646
[TBL] [Abstract][Full Text] [Related]
16. Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests.
Jones RN; Barry AL; Thornsberry C; Gerlach EH; Fuchs PC; Gavan TL; Sommers HM
J Antimicrob Chemother; 1981 Sep; 8 Suppl B():187-211. PubMed ID: 19802985
[TBL] [Abstract][Full Text] [Related]
17. The in vitro activity and beta-lactamase stability of cefpirome (HR 810), a pyridine cephalosporin agent active against staphylococci, Enterobacteriaceae and Pseudomonas aeruginosa.
Neu HC; Chin NX; Labthavikul P
Infection; 1985; 13(3):146-55. PubMed ID: 3928497
[TBL] [Abstract][Full Text] [Related]
18. In vitro evaluation of cefepime and other broad-spectrum beta-lactams against bacteria from Indonesian medical centers. The Indonesia Antimicrobial Resistance Study Group.
Lewis MT; Biedenbach DJ; Jones RN
Diagn Microbiol Infect Dis; 1999 Dec; 35(4):285-90. PubMed ID: 10668587
[TBL] [Abstract][Full Text] [Related]
19. [Activity of cefpirome against bacteria isolated from hospitalized patients].
Fernández A; Herran I; de Mier C; Marcenac FM
Medicina (B Aires); 1989; 49(4):373-8. PubMed ID: 2487748
[TBL] [Abstract][Full Text] [Related]
20. In vitro antibacterial activity of FK037, a novel parenteral broad-spectrum cephalosporin.
Mine Y; Watanabe Y; Sakamoto H; Hatano K; Kuno K; Higashi Y; Kamimura T; Matsumoto Y; Tawara S; Matsumoto F
J Antibiot (Tokyo); 1993 Jan; 46(1):71-87. PubMed ID: 8436562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
